Annual CFF
$748.46 M
+$296.92 M+65.76%
December 31, 2024
Summary
- As of March 17, 2025, BBIO annual cash flow from financing activities is $748.46 million, with the most recent change of +$296.92 million (+65.76%) on December 31, 2024.
- During the last 3 years, BBIO annual CFF has risen by +$12.01 million (+1.63%).
- BBIO annual CFF is now at all-time high.
Performance
BBIO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$473.93 M
+$473.22 M+66934.09%
December 31, 2024
Summary
- As of March 17, 2025, BBIO quarterly cash flow from financing activities is $473.93 million, with the most recent change of +$473.22 million (+66934.09%) on December 31, 2024.
- Over the past year, BBIO quarterly CFF has increased by +$473.22 million (+66934.09%).
- BBIO quarterly CFF is now -13.50% below its all-time high of $547.91 million, reached on March 31, 2021.
Performance
BBIO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$748.46 M
+$478.45 M+177.20%
December 31, 2024
Summary
- As of March 17, 2025, BBIO TTM cash flow from financing activities is $748.46 million, with the most recent change of +$478.45 million (+177.20%) on December 31, 2024.
- Over the past year, BBIO TTM CFF has increased by +$478.45 million (+177.20%).
- BBIO TTM CFF is now -11.98% below its all-time high of $850.29 million, reached on June 30, 2020.
Performance
BBIO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
BBIO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +65.8% | +10000.0% | +177.2% |
| 3 y3 years | +1.6% | +10000.0% | +177.2% |
| 5 y5 years | +87.7% | +10000.0% | +177.2% |
BBIO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5798.6% | at high | +2378.9% | at high | +5798.6% |
| 5 y | 5-year | at high | +5798.6% | -13.5% | +449.9% | -12.0% | +5798.6% |
| alltime | all time | at high | +5798.6% | -13.5% | +449.9% | -12.0% | +5798.6% |
BridgeBio Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $748.46 M(+65.8%) | $473.93 M(>+9900.0%) | $748.46 M(+177.2%) |
| Sep 2024 | - | $707.00 K(-112.3%) | $270.00 M(-53.2%) |
| Jun 2024 | - | -$5.73 M(-102.0%) | $576.34 M(-0.8%) |
| Mar 2024 | - | $279.55 M(-6280.6%) | $580.83 M(+28.6%) |
| Dec 2023 | $451.54 M(-3537.9%) | -$4.52 M(-101.5%) | $451.54 M(-2.4%) |
| Sep 2023 | - | $307.04 M(<-9900.0%) | $462.44 M(+194.8%) |
| Jun 2023 | - | -$1.23 M(-100.8%) | $156.84 M(+14.3%) |
| Mar 2023 | - | $150.25 M(+2256.1%) | $137.28 M(-1145.2%) |
| Dec 2022 | -$13.13 M(-101.8%) | $6.38 M(+341.3%) | -$13.13 M(-104.3%) |
| Sep 2022 | - | $1.45 M(-106.9%) | $305.87 M(+81.0%) |
| Jun 2022 | - | -$20.80 M(>+9900.0%) | $168.97 M(-10.3%) |
| Mar 2022 | - | -$160.00 K(-100.0%) | $188.37 M(-74.4%) |
| Dec 2021 | $736.45 M | $325.38 M(-340.2%) | $736.45 M(+77.2%) |
| Sep 2021 | - | -$135.46 M(+9638.0%) | $415.60 M(-25.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$1.39 M(-100.3%) | $553.83 M(-0.4%) |
| Mar 2021 | - | $547.91 M(>+9900.0%) | $555.93 M(+24.3%) |
| Dec 2020 | $447.19 M(+12.1%) | $4.53 M(+62.9%) | $447.19 M(-7.9%) |
| Sep 2020 | - | $2.78 M(+295.7%) | $485.56 M(-42.9%) |
| Jun 2020 | - | $703.00 K(-99.8%) | $850.29 M(+1.3%) |
| Mar 2020 | - | $439.17 M(+923.6%) | $839.62 M(+110.5%) |
| Dec 2019 | $398.79 M(-20.5%) | $42.90 M(-88.3%) | $398.79 M(-36.7%) |
| Sep 2019 | - | $367.51 M(-3786.5%) | $630.06 M(+141.6%) |
| Jun 2019 | - | -$9.97 M(+503.8%) | $260.83 M(-46.1%) |
| Mar 2019 | - | -$1.65 M(-100.6%) | $484.20 M(-3.5%) |
| Dec 2018 | $501.55 M(+343.9%) | $274.17 M(<-9900.0%) | $501.55 M(+120.6%) |
| Sep 2018 | - | -$1.73 M(-100.8%) | $227.37 M(-0.8%) |
| Jun 2018 | - | $213.41 M(+1259.9%) | $229.10 M(+1359.9%) |
| Mar 2018 | - | $15.69 M | $15.69 M |
| Dec 2017 | $112.98 M | - | - |
FAQ
- What is BridgeBio Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for BridgeBio Pharma?
- What is BridgeBio Pharma annual CFF year-on-year change?
- What is BridgeBio Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BridgeBio Pharma?
- What is BridgeBio Pharma quarterly CFF year-on-year change?
- What is BridgeBio Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for BridgeBio Pharma?
- What is BridgeBio Pharma TTM CFF year-on-year change?
What is BridgeBio Pharma annual cash flow from financing activities?
The current annual CFF of BBIO is $748.46 M
What is the all time high annual CFF for BridgeBio Pharma?
BridgeBio Pharma all-time high annual cash flow from financing activities is $748.46 M
What is BridgeBio Pharma annual CFF year-on-year change?
Over the past year, BBIO annual cash flow from financing activities has changed by +$296.92 M (+65.76%)
What is BridgeBio Pharma quarterly cash flow from financing activities?
The current quarterly CFF of BBIO is $473.93 M
What is the all time high quarterly CFF for BridgeBio Pharma?
BridgeBio Pharma all-time high quarterly cash flow from financing activities is $547.91 M
What is BridgeBio Pharma quarterly CFF year-on-year change?
Over the past year, BBIO quarterly cash flow from financing activities has changed by +$473.22 M (+66934.09%)
What is BridgeBio Pharma TTM cash flow from financing activities?
The current TTM CFF of BBIO is $748.46 M
What is the all time high TTM CFF for BridgeBio Pharma?
BridgeBio Pharma all-time high TTM cash flow from financing activities is $850.29 M
What is BridgeBio Pharma TTM CFF year-on-year change?
Over the past year, BBIO TTM cash flow from financing activities has changed by +$478.45 M (+177.20%)